

Global and United States Atypical Hemolytic Uremic Syndrome Drug In-Depth Research Report 2017-2022

<https://marketpublishers.com/r/GCAEF436AC3EN.html>

Date: December 2017

Pages: 109

Price: US\$ 3,190.00 (Single User License)

ID: GCAEF436AC3EN

Abstracts

The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022.

This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Atypical Hemolytic Uremic Syndrome Drug industry.

Major Companies

Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Amgen Inc
ChemoCentryx Inc
greenovation Biotech GmbH
Kedrion SpA
Omeros Corp

Key Regions

North America
United States
California
Texas
New York

Others

Canada

Latin America

Mexico

Brazil

Argentina

Others

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Netherland

Others

Asia & Pacific

China

Japan

India

Korea

Australia

Southeast Asia

Indonesia

Thailand

Philippines

Vietnam

Singapore

Malaysia

Others

Africa & Middle East

South Africa

Egypt

Turkey

Saudi Arabia

Iran

Others

Main types of products

Atypical Hemolytic Uremic Syndrome Drug Market, byN-CC5

Atypical Hemolytic Uremic Syndrome Drug Market, byX-168

Atypical Hemolytic Uremic Syndrome Drug Market, by-006

Atypical Hemolytic Uremic Syndrome Drug Market, byR-001

Atypical Hemolytic Uremic Syndrome Drug Market, bybodina

Atypical Hemolytic Uremic Syndrome Drug Market, by Key Consumers

Clinic

Hospital

Others

Contents

CHAPTER ONE GLOBAL ATYPICAL HEMOLYTIC UREMIC SYNDROME DRUG MARKET OVERVIEW

1.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Sales Volume Revenue and Price 2012-2017

1.2 Atypical Hemolytic Uremic Syndrome Drug, by -CC5 2012-2017

1.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by -CC5 2012-2017

1.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by -CC5 2012-2017

1.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by -CC5 2012-2017

1.2.4

1.2.5

1.3 Atypical Hemolytic Uremic Syndrome Drug, by -168 2012-2017

1.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by -168 2012-2017

1.3.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by -168 2012-2017

1.3.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by -168 2012-2017

1.3.4

1.3.5

1.4 Atypical Hemolytic Uremic Syndrome Drug, by 006 2012-2017

1.4.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by 006 2012-2017

1.4.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by 006 2012-2017

1.4.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by 006 2012-2017

1.4.4

1.4.5

1.5 Atypical Hemolytic Uremic Syndrome Drug, by -001 2012-2017

1.5.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by -001 2012-2017

1.5.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by -001 2012-2017

1.5.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by -001 2012-2017

1.5.4

1.5.5

1.6 Atypical Hemolytic Uremic Syndrome Drug, by odina 2012-2017

1.6.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by odina 2012-2017

1.6.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by odina 2012-2017

1.6.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by odina 2012-2017

1.6.4

1.6.5

CHAPTER TWO UNITED STATES ATYPICAL HEMOLYTIC UREMIC SYNDROME DRUG MARKET OVERVIEW

2.1 United States Atypical Hemolytic Uremic Syndrome Drug Market Sales Volume Revenue and Price 2012-2017

2.2 Atypical Hemolytic Uremic Syndrome Drug, by -CC5 2012-2017

2.2.1 United States Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by -CC5 2012-2017

2.2.2 United States Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by -CC5 2012-2017

2.2.3 United States Atypical Hemolytic Uremic Syndrome Drug Price by -CC5 2012-2017

2.2.4

2.2.5

2.3 Atypical Hemolytic Uremic Syndrome Drug, by -168 2012-2017

2.3.1 United States Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by -168 2012-2017

2.3.2 United States Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by -168 2012-2017

2.3.3 United States Atypical Hemolytic Uremic Syndrome Drug Price by -168 2012-2017

2.3.4

2.3.5

2.4 Atypical Hemolytic Uremic Syndrome Drug, by 006 2012-2017

2.4.1 United States Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by 006 2012-2017

2.4.2 United States Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by 006 2012-2017

2.4.3 United States Atypical Hemolytic Uremic Syndrome Drug Price by 006 2012-2017

2.4.4

2.4.5

2.5 Atypical Hemolytic Uremic Syndrome Drug, by -001 2012-2017

2.5.1 United States Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by -001 2012-2017

2.5.2 United States Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by -001 2012-2017

2.5.3 United States Atypical Hemolytic Uremic Syndrome Drug Price by -001 2012-2017

2.5.4

2.5.5

2.6 Atypical Hemolytic Uremic Syndrome Drug, by odina 2012-2017

2.6.1 United States Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by odina 2012-2017

2.6.2 United States Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by odina 2012-2017

2.6.3 United States Atypical Hemolytic Uremic Syndrome Drug Price by odina 2012-2017

2.6.4

2.6.5

CHAPTER THREE ATYPICAL HEMOLYTIC UREMIC SYNDROME DRUG BY REGIONS 2012-2017

3.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Regions 2012-2017

3.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Regions 2012-2017

3.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by Regions 2012-2017

3.4 North America

3.4.1 United States

3.4.1.1 California

3.4.1.2 Texas

3.4.1.3 New York

3.4.1.4 Others in United States

3.4.2 Canada

3.5 Latin America

3.5.1 Mexico

3.5.2 Brazil

- 3.5.3 Argentina
- 3.5.4 Others in Latin America
- 3.6 Europe
 - 3.6.1 Germany
 - 3.6.2 United Kingdom
 - 3.6.3 France
 - 3.6.4 Italy
 - 3.6.5 Spain
 - 3.6.6 Russia
 - 3.6.7 Netherland
 - 3.6.8 Others in Europe
- 3.7 Asia & Pacific
 - 3.7.1 China
 - 3.7.2 Japan
 - 3.7.3 India
 - 3.7.4 Korea
 - 3.7.5 Australia
 - 3.7.6 Southeast Asia
 - 3.7.6.1 Indonesia
 - 3.7.6.2 Thailand
 - 3.7.6.3 Philippines
 - 3.7.6.4 Vietnam
 - 3.7.6.5 Singapore
 - 3.7.6.6 Malaysia
 - 3.7.6.7 Others in Southeast Asia
- 3.8 Africa & Middle East
 - 3.8.1 South Africa
 - 3.8.2 Egypt
 - 3.8.3 Turkey
 - 3.8.4 Saudi Arabia
 - 3.8.5 Iran
 - 3.8.6 Others in Africa & Middle East

CHAPTER FOUR GLOBAL ATYPICAL HEMOLYTIC UREMIC SYNDROME DRUG BY COMPANIES 2012-2017

- 4.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume Market Share by Companies 2012-2017
- 4.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Companies

2012-2017

4.3 Global Top Companies Atypical Hemolytic Uremic Syndrome Drug Key Product Model and Market Performance

4.4 Global Top Companies Atypical Hemolytic Uremic Syndrome Drug Key Target Consumers and Market Performance

CHAPTER FIVE UNITED STATES ATYPICAL HEMOLYTIC UREMIC SYNDROME DRUG BY COMPANIES 2012-2017

5.1 United States Atypical Hemolytic Uremic Syndrome Drug Sales Volume Market Share by Companies 2012-2017

5.2 United States Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Companies 2012-2017

5.3 United States Top Companies Atypical Hemolytic Uremic Syndrome Drug Key Product Model and Market Performance

5.4 United States Top Companies Atypical Hemolytic Uremic Syndrome Drug Key Target Consumers and Market Performance

CHAPTER SIX GLOBAL ATYPICAL HEMOLYTIC UREMIC SYNDROME DRUG BY CONSUMER 2012-2017

6.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Consumer 2012-2017

6.2 Clinic

6.3 Hospital

6.4 Others

6.5 Consuming Habit and Preference

CHAPTER SEVEN GLOBAL ATYPICAL HEMOLYTIC UREMIC SYNDROME DRUG BY CONSUMER 2012-2017

7.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Consumer 2012-2017

7.2 Clinic

7.3 Hospital

7.4 Others

7.5 Consuming Habit and Preference

CHAPTER EIGHT TOP COMPANIES PROFILE

8.1 Achillion Pharmaceuticals Inc

8.1.1 Achillion Pharmaceuticals Inc Company Details and Competitors

8.1.2 Achillion Pharmaceuticals Inc Key Atypical Hemolytic Uremic Syndrome Drug Models and Performance

8.1.3 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Business SWOT Analysis and Forecast

8.1.4 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

8.2 Akari Therapeutics Plc

8.2.1 Akari Therapeutics Plc Company Details and Competitors

8.2.2 Akari Therapeutics Plc Key Atypical Hemolytic Uremic Syndrome Drug Models and Performance

8.2.3 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Business SWOT Analysis and Forecast

8.2.4 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

8.3 Alexion Pharmaceuticals Inc

8.3.1 Alexion Pharmaceuticals Inc Company Details and Competitors

8.3.2 Alexion Pharmaceuticals Inc Key Atypical Hemolytic Uremic Syndrome Drug Models and Performance

8.3.3 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Business SWOT Analysis and Forecast

8.3.4 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

8.4 Amgen Inc

8.4.1 Amgen Inc Company Details and Competitors

8.4.2 Amgen Inc Key Atypical Hemolytic Uremic Syndrome Drug Models and Performance

8.4.3 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Business SWOT Analysis and Forecast

8.4.4 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

8.5 ChemoCentryx Inc

8.5.1 ChemoCentryx Inc Company Details and Competitors

8.5.2 ChemoCentryx Inc Key Atypical Hemolytic Uremic Syndrome Drug Models and Performance

8.5.3 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Business SWOT Analysis and Forecast

8.5.4 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

8.6 greenovation Biotech GmbH

8.6.1 greenovation Biotech GmbH Company Details and Competitors

8.6.2 greenovation Biotech GmbH Key Atypical Hemolytic Uremic Syndrome Drug Models and Performance

8.6.3 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Business SWOT Analysis and Forecast

8.6.4 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

8.7 Kedrion SpA

8.7.1 Kedrion SpA Company Details and Competitors

8.7.2 Kedrion SpA Key Atypical Hemolytic Uremic Syndrome Drug Models and Performance

8.7.3 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Business SWOT Analysis and Forecast

8.7.4 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

8.8 Omeros Corp

8.8.1 Omeros Corp Company Details and Competitors

8.8.2 Omeros Corp Key Atypical Hemolytic Uremic Syndrome Drug Models and Performance

8.8.3 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Business SWOT Analysis and Forecast

8.8.4 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin

CHAPTER NINE INDUSTRY CHAIN AND SUPPLY CHAIN

9.1 Atypical Hemolytic Uremic Syndrome Drug Industry Chain Structure

9.1.1 R&D

9.1.2 Raw Materials (Components)

9.1.3 Manufacturing Plants

9.1.4 Regional Trading (Import Export and Local Sales)

9.1.5 Online Sales Channel

9.1.6 Offline Channel

9.1.7 End Users

9.2 Atypical Hemolytic Uremic Syndrome Drug Manufacturing

9.2.1 Key Components

- 9.2.2 Assembly Manufacturing
- 9.3 Consumer Preference
- 9.4 Behavioral Habits
- 9.5 Marketing Environment

CHAPTER TEN GLOBAL ATYPICAL HEMOLYTIC UREMIC SYNDROME DRUG MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

- 10.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
- 10.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by Regions (2017-2022)
- 10.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by Application (2017-2022)
- 10.4 Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by -CC5 (2017-2022)
- 10.5 Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by -168 (2017-2022)
- 10.6 Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by 006 (2017-2022)
- 10.7 Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by -001 (2017-2022)
- 10.8 Global Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by odina (2017-2022)

CHAPTER ELEVEN UNITED STATES ATYPICAL HEMOLYTIC UREMIC SYNDROME DRUG MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

- 11.1 United States Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
- 11.2 United States Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by Regions (2017-2022)
- 11.3 United States Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by Application (2017-2022)
- 11.4 United States Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by -CC5 (2017-2022)
- 11.5 United States Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by -168 (2017-2022)

11.6 United States Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by 006 (2017-2022)

11.7 United States Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by -001 (2017-2022)

11.8 United States Atypical Hemolytic Uremic Syndrome Drug Sales (K Pcs) Forecast by odina (2017-2022)

CHAPTER TWELVE DEVELOPMENT TREND AND RESEARCH CONCLUSION

12.1 Development Trend

12.2 Research Conclusion

CHAPTER THIRTEEN METHODOLOGY AND DATA SOURCE

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Table Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume (K Pcs),
Revenue (Million USD) and Price (USD/Pcs)(2012-2017)

Figure Global Atypical Hemolytic Uremic Syndrome Drug Revenue (Millio

I would like to order

Product name: Global and United States Atypical Hemolytic Uremic Syndrome Drug In-Depth Research Report 2017-2022

Product link: <https://marketpublishers.com/r/GCAEF436AC3EN.html>

Price: US\$ 3,190.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCAEF436AC3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

